HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

被引：0
|
作者：
Miller, Kathy
Cortes, Javier
Hurvitz, Sara A.
Krop, Ian E.
Tripathy, Debu
Verma, Sunil
Riahi, Kaveh
Reynolds, Joseph G.
Wickham, Thomas J.
Molnar, Istvan
Yardley, Denise A.
机构：
[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Vall DHebron Univ Hosp, Barcelona, Spain
[3] UCLA Healthcare Hematol Oncol Breast Oncol Progra, Santa Monica, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[7] Merrimack Pharma, Cambridge, MA USA
[8] Merrimack Pharmaceut Inc, Cambridge, MA USA
[9] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps641
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS641
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Lu, D.
    Krop, I.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Huang, J.
    Lu, M.
    Girish, S.
    [J]. CANCER RESEARCH, 2010, 70
  • [42] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    [J]. ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [44] Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice
    Ferraro, Gino B.
    Askoxylakis, Vasileios
    Kodack, David P.
    Badeaux, Mark
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    [J]. CANCER RESEARCH, 2016, 76
  • [45] Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
    Emens, Leisha A.
    Esteva, Francisce J.
    Beresford, Mark
    Saura, Cristina
    De Laurentiis, Michelin
    Kim, Sung-Bae
    Im, Seock-Ah
    Wang, Yifan
    Salgado, Roberto
    Mani, Aruna
    Shah, Jigna
    Lambertini, Chiara
    Liu, Haiying
    de Haas, Sanne L.
    Patre, Monika
    Loi, Sherene
    [J]. LANCET ONCOLOGY, 2020, 21 (10): : 1283 - 1295
  • [46] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer A Phase 1 and Randomized Phase 2 Trial
    Cortes, Javier
    Dieras, Veronique
    Lorenzen, Sylvie
    Montemurro, Filippo
    Riera-Knorrenschild, Jorge
    Thuss-Patience, Peter
    Allegrini, Giacomo
    De Laurentiis, Michelino
    Lohrisch, Caroline
    Oravcova, Eva
    Perez-Garcia, Jose M.
    Ricci, Francesco
    Sakaeva, Dina
    Serpanchy, Rosanne
    Sufliarsky, Jozef
    Vidal, Maria
    Irahara, Natsumi
    Wohlfarth, Christine
    Aout, Mounir
    Gelmon, Karen
    [J]. JAMA ONCOLOGY, 2020, 6 (08) : 1203 - 1209
  • [48] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Denduluri, Neelima
    Espirito, Janet L.
    Hackshaw, Michelle D.
    Wentworth, Chuck
    Recchia, Tamy
    Kwong, Winghan J.
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 177 - 186
  • [49] A Dose-Escalation Study of Trastuzumab-DM1 (T-DM1), Paclitaxel (T), and Pertuzumab (P) in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen
    Krop, I. E.
    Modi, S.
    Elias, A.
    LoRusso, P.
    Choi, Y. J.
    Lu, M.
    [J]. CANCER RESEARCH, 2010, 70
  • [50] Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
    Im, S-A.
    Park, I.
    Sohn, J. H.
    Im, Y-H.
    Lee, S. C.
    Chang, H-K.
    Macharia, H.
    Sun, G.
    Lamour, F.
    Oh, D-Y.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S488 - S489
12345